MangoRx IP Holdings, LLC, a former subsidiary of Mangoceuticals, Inc., has entered into agreements for a $2.5 million strategic investment. The company reported receiving the first $1.75 million tranche of the funds. These transactions occur at the subsidiary level and do not result in the issuance of any Mangoceuticals common stock, warrants, or other securities, thereby leaving the parent company's public capitalization structure unchanged.
Under the subscription agreements, two investors have committed to purchasing an aggregate 25% membership interest in MangoRx IP for the total sum. The initial payment covers a 17.5% post-acquisition membership interest. The remaining 7.5% interest is tied to a second payment of $750,000, which is due within 60 days of the initial closing or by November 28, 2026, subject to the specific terms of the agreement.
MangoRx IP holds the patent portfolio for MGX-0024, an antiviral technology involving oral-surface preparations intended to prevent illnesses entering through the mouth and throat. The company indicates this technology could be applied in poultry, livestock feed and water additives, and human oral-care products such as toothpaste, mouthwash, lozenges, and sprays. Citing Fortune Business Insights, Mangoceuticals noted that the global oral care market was valued at roughly $34.8 billion in 2025, while the global feed additives market stood at approximately $39.8 billion that same year.
Jacob Cohen, founder and chief executive officer of Mangoceuticals, stated that the investment validates the value built within MangoRx IP and provides capital for commercialization without diluting public shareholders. He explained that structuring the deal at the subsidiary level was designed to secure outside capital while preserving the parent company's capital structure. Cohen added that having strategic investors aligned with MangoRx IP strengthens the company's position for potential licensing and distribution opportunities.
The patent portfolio is protected in the U.S. under Patent No. 11,517,523. The company reported that similar patents are either already issued or currently seeking approval in the EU, Canada, China, India, Australia, and Japan. The membership interests are being sold in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D. These securities have not been registered under federal or state securities laws.